Syntekabio Inc. Selected for Ministry of SMEs 2024 Industry-Academia-Research Collabo R&D Program... Commencing AI-Based Psoriasis Treatment Development
▶ Syntekabio-Sogang University, RudaCure-Inje University... Synergy expected through multidisciplinary collaboration
▶ Government R&D support to foster national strategic technologies and regional strategic industries
Syntekabio Inc. (CEO Jongsun Jeong) announced that it has been selected for the '2024 Industry-Academia-Research Collabo R&D' program (preliminary research) supported by the Ministry of SMEs and Startups and signed the agreement on the 12th.
This research aims to discover novel drug candidates for psoriasis treatment and will demonstrate the efficiency of an AI-based drug development platform.
Syntekabio has formed an industry-academia-research consortium with RudaCure Inc., Sogang University, and Inje University to jointly conduct this research. The research topic is 'Development of selective modulators for psoriasis target proteins using an AI drug platform,' with a total research period from May 2025 to May 2026.
Syntekabio's AI drug development platform 'STB' was used for computer-based target protein analysis and candidate compound discovery. RudaCure's TRPV1 modulation technology expertise provides specialized knowledge in skin disease-related ion channel research. Sogang University is responsible for compound synthesis and optimization, while Inje University handles in-vitro and in-vivo efficacy evaluation of candidate compounds.
CEO Jongsun Jeong of Syntekabio stated, "Through AI-based drug development, we will pioneer new possibilities in the psoriasis treatment market. Through collaboration with excellent partners like RudaCure, Sogang University, and Inje University, we expect outstanding results."